Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $281.49 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EVOKE PHARMA, INC. | $120.83 | 1 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $44.51 | 3 | $0 (2022) |
| Merck Sharp & Dohme LLC | $36.53 | 2 | $0 (2022) |
| Novo Nordisk Inc | $21.76 | 1 | $0 (2022) |
| Actelion Pharmaceuticals US, Inc. | $17.41 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $14.62 | 1 | $0 (2021) |
| GENZYME CORPORATION | $12.96 | 1 | $0 (2022) |
| Allergan, Inc. | $12.87 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $138.24 | 2 | EVOKE PHARMA, INC. ($120.83) |
| 2022 | $67.05 | 4 | Novo Nordisk Inc ($21.76) |
| 2021 | $14.62 | 1 | AstraZeneca Pharmaceuticals LP ($14.62) |
| 2020 | $61.58 | 4 | Janssen Pharmaceuticals, Inc ($29.13) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Cardiology | ||||||
| 01/18/2024 | EVOKE PHARMA, INC. | GIMOTI (Drug) | Food and Beverage | In-kind items and services | $120.83 | General |
| Category: Gastroenterology | ||||||
| 11/16/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/05/2022 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $12.96 | General |
| 03/29/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/13/2022 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $21.76 | General |
| 08/27/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/22/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/14/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/22/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 91 | 153 | $33,399 | $12,840 |
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 66 | $14,124 | $6,047 | 42.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 45 | $7,425 | $2,741 | 36.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $5,516 | $1,821 | 33.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $3,679 | $1,303 | 35.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 15 | $2,655 | $927.90 | 34.9% |
About Dr. Yuliya Fedchik, DO
Dr. Yuliya Fedchik, DO is a Internal Medicine healthcare provider based in Parma, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2020. The National Provider Identifier (NPI) number assigned to this provider is 1689203325.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yuliya Fedchik, DO has received a total of $281.49 in payments from pharmaceutical and medical device companies, with $138.24 received in 2024. These payments were reported across 11 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($281.49).
As a Medicare-enrolled provider, Fedchik has provided services to 91 Medicare beneficiaries, totaling 153 services with total Medicare billing of $12,840. Data is available for 1 year (2023–2023), covering 5 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Parma, OH
- Active Since 04/04/2020
- Last Updated 09/29/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1689203325
Products in Payments
- GIMOTI (Drug) $120.83
- XARELTO (Drug) $44.51
- ZERBAXA (Drug) $36.53
- OPSUMIT (Drug) $17.41
- BRILINTA (Drug) $14.62
- UBRELVY (Drug) $12.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Parma
Dr. Charles Koepke, Md, MD
Internal Medicine — Payments: $10,439
Jason Ice, Do, DO
Internal Medicine — Payments: $10,215
Florin Penciu, Md, MD
Internal Medicine — Payments: $9,339
Dr. Boris Gliner, M.d, M.D
Internal Medicine — Payments: $7,878
Dr. Morgan Koepke, Md, MD
Internal Medicine — Payments: $7,488
Amir Naraghi, Md, MD
Internal Medicine — Payments: $4,620